Search Results
May 28, 2026, 13:15 ET Braeburn Presents New Data at 2026 ASCP Annual Meeting Demonstrating Opioid Withdrawal Suppression at Low Buprenorphine Plasma Concentrations
with the REMS requirements.BRIXADI (buprenorphine) extended-release injection (weekly, 50 mg/mL buprenorphine) and BRIXADI (monthly, 356 mg/mL buprenorphine) are different formulations. Doses of BRIXADI (weekly) cannot be combined to yield an equivalent monthly dose.CONTRAINDICATIONSBRIXADI
More news about: Braeburn
May 28, 2026, 13:00 ET Lilly to present new data on Foundayo, Mounjaro and retatrutide at the American Diabetes Association's 86th Scientific Sessions, building toward a new era of choice in diabetes and obesity care
moreMounjaro is a prescription medicine available as a pre-filled single-dose pen in 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, or 15 mg per 0.5 mL injection. For more information, call 1-800-LillyRX (800-545-5979) [or go to
More news about: Eli Lilly and Company
May 28, 2026, 11:32 ET NeuLogiq® Platform Helps Confirm No Evidence of Psychotomimetic, Hallucinatory, or Dissociative Effects in a Phase 1b Study of a Novel Neuroplastogen Developed for Major Depressive Disorder
clinical data repeatedly over time, across multiple behavioral and physiological domains, in the clinic and at home. Together with machine learning (ML) analytics, Cumulus simplifies and improves the robustness of CNS clinical trials, providing objective assessment of study inclusion and treatment outcomes.About
More news about: Cumulus Neuroscience
May 28, 2026, 10:08 ET Kythera Labs Launches Wayfinder DataSync to Help Health Systems Improve Visibility Into Patient Movement and Market Opportunity
in annualized economic value associated with retained encounters.Wayfinder DataSync is built with privacy-preserving tokenization, ML-driven patient mastering, and continuous governance capabilities designed to support secure, compliant, and scalable integration of healthcare data sources.About
More news about: Kythera Labs
May 28, 2026, 09:05 ET CUMBERLAND PHARMACEUTICALS ANNOUNCES LAUNCH OF VIBATIV® IN CHINA
cure rates for telavancin as compared to vancomycin in HABP/VABP due to any single Gram-positive pathogen or S. aureus with vancomycin MIC ≥1 µg/mL. Additionally, there is extensive and well-documented evidence of the drug's in vitro potency and in vivo activity against a broad collection
More news about: Cumberland Pharmaceuticals Inc.
May 28, 2026, 09:00 ET Wiliot Collaborates with AT&T Business as Demand for Physical AI in Enterprise Supply Chains Accelerates Internationally
location and condition. The Wiliot Physical AI platform processes signals from battery-free Bluetooth sensors (IoT Pixels) using purpose-built AI and ML models. This enables real-time automated condition monitoring, inventory intelligence, and workflow optimization. Whether you have AI in place or are
More news about: Wiliot
May 28, 2026, 06:59 ET Data Center Direct-to-Chip Coolants Market worth $1.30 billion by 2032 - Exclusive Report by MarketsandMarkets™
direct-to-chip cooling technologies to accommodate high-density computing configurations associated with artificial intelligence (AI), machine learning (ML), high-performance computing (HPC), and extensive cloud workloads. The rising implementation of AI accelerators and next-generation graphics processing
More news about: MarketsandMarkets
May 28, 2026, 06:00 ET Landmark Study Published in the Journal of the American Medical Association (JAMA) Surgery Validates Bridge to Life's VitaSmart™ HOPE Perfusion System as a Superior Organ Preservation Technology
medical-association-jama-surgery-validates-bridge-to-lifes-vitasmart-hope-perfusion-system-as-a-superior-organ-preservation-technology-302783631.htmlSOURCE Bridge to Life, Ltd.
More news about: Bridge to Life, Ltd.
May 28, 2026, 04:21 ET Aphranel® MagiCCrystal CaHA Filler Achieves EU MDR Certification as a Premium Regenerative Injectable
medical aesthetics market, Aphranel is positioned as a high-end regenerative injectable product, with a recommended retail price of RMB 12,800 per 0.5 mL syringe.Aphranel has also introduced the concept of "The Poetics of Time," reflecting its focus on regenerative aesthetics, gradual improvement,
More news about: SHANGHAI MOYOM BIOTECHNOLOGY CO., LTD; Aphranel
May 28, 2026, 03:55 ET Aphranel® MagiCCrystal CaHA Filler Achieves EU MDR Certification as a Premium Regenerative Injectable
medical aesthetics market, Aphranel is positioned as a high-end regenerative injectable product, with a recommended retail price of RMB 12,800 per 0.5 mL syringe.Aphranel has also introduced the concept of "The Poetics of Time," reflecting its focus on regenerative aesthetics, gradual improvement,
More news about: SHANGHAI MOYOM BIOTECHNOLOGY CO., LTD; Aphranel
May 27, 2026, 23:59 ET Sidus Space Announces Pricing of $100 Million Registered Direct Offering of Class A Common Stock
solutions, including satellite manufacturing and technology integration, AI-driven space-based data solutions, mission planning and management operations, AI/ML products and services, and space and defense hardware manufacturing. With its mission of Space Access Reimagined®, Sidus Space is committed to rapid
More news about: Sidus Space, Inc.
May 27, 2026, 11:00 ET PASSOÃ UNVEILS NEW BOTTLE DESIGN AS TROPICAL COCKTAIL CULTURE CONTINUES TO SURGE
consistency and strong cocktail economics behind the bar.To support both retail and on-premise execution, the new packaging will launch in a 750ml format alongside a new 1L size developed specifically for bars and restaurants, helping operators improve speed, efficiency, and back-bar visibility.According
More news about: Lucas Bols
May 27, 2026, 10:55 ET Cloudelligent and Honeycomb Partner to Bring Enterprise Observability to AWS-Native Organizations in the AI Era
to:Migrate and modernize legacy environments to AWSBuild cloud-native and Kubernetes-based architecturesAdopt AI and ML workloads responsiblyEnsure the observability infrastructure needed to operate with confidenceBy pairing Cloudelligent's AWS modernization
More news about: Cloudelligent
May 27, 2026, 09:00 ET Doppel Announces Agentic Email Security Solution to Stop Malicious Campaigns, Not Just Messages
introducing email security that finally fights back. It starts with an agentic architecture driven by natural language detection policies, rather than blackbox ML or whitebox YARA rules, and supports continuous patching on misses. Furthermore, with Doppel, companies can investigate the broader operations behind
More news about: Doppel
May 27, 2026, 09:00 ET Workera Releases AI Readiness Assessments Aligned to Evolving Industry Standards
engineers, solutions architects, and AI application developersScientist: Deep Learning Advanced Prompts, Agents & RAG for data scientists, ML researchers, and AI modelersSteward: Agentic AI Fluency and AI Adoption for Leaders for executives, department heads, CAIOs, and compliance
More news about: Workera
May 27, 2026, 09:00 ET If you purchased raw Beef product in the United States from January 1, 2015, through May 6, 2026, for business use in commercial food preparation, a class action settlement may affect your rights
rom-january-1-2015-through-may-6-2026-for-business-use-in-commercial-food-preparation-a-class-action-settlement-may-affect-your-rights-302782210.html
More news about: The United States District Court for the District of Minnesota
May 27, 2026, 09:00 ET Linux Foundation Announces DNS-AID Project to Advance Decentralized AI Agent Discovery
innovation. As AI ecosystems continue to evolve, domains, the DNS, and their associated security protocols will become a foundational trust layer for AI, ML, and LLM-driven systems, enabling agent identity, routing, security, and policy enforcement. Through the monitoring and enforcement of daily domain name
More news about: The Linux Foundation
May 27, 2026, 08:00 ET Verge Labs Launches as a Frontier AI Lab for Human Disease Biology
Altos Labs, where he served as Senior ML Research Engineer. At Altos, he built state-of-the-art virtual cell models that won the 2025 Arc Virtual Cell Competition generalist prize and led the open-source release of PerturBench, the field's standard benchmark for ML models of cellular perturbation response.
More news about: Verge Labs
May 27, 2026, 08:00 ET Trumid Launches Full Self Trading (FST™), Advancing Cross-Protocol Execution in Credit Trading
with Attributed Trading integration planned for H2 2026Adaptive Execution Logic – Leveraging Trumid's proprietary pricing intelligence, ML-driven models, and analytics to evaluate opportunities and adjust behavior in real timeConfigurable Execution Strategies – Aligning execution
More news about: Trumid
May 27, 2026, 08:00 ET From Hit Identification to Lead Optimization: Building Scientific Continuity in Early Drug Discovery
focused compound sets.Structure-based design, ligand-centric SAR analysis, molecular descriptors, FEP, MD simulations, ADMET prediction, and AI/ML-supported modeling can all contribute to compound prioritization. The objective is not to generate designs in isolation, but to test defined hypotheses
More news about: Viva Biotech
May 27, 2026, 08:00 ET From Hit Identification to Lead Optimization: Building Scientific Continuity in Early Drug Discovery
focused compound sets.Structure-based design, ligand-centric SAR analysis, molecular descriptors, FEP, MD simulations, ADMET prediction, and AI/ML-supported modeling can all contribute to compound prioritization. The objective is not to generate designs in isolation, but to test defined hypotheses
More news about: Viva Biotech
May 27, 2026, 07:00 ET Brii Bio Presents Late-Breaking Data from Its Phase 2 ENSURE Study at EASL Congress 2026, Further Supporting the Potential Role of BRII-179 in Achieving Durable Immunological Control of HBV
participants achieving functional cure had a baseline HBsAg levels below 1,000 IU/mL in the ENSURE study, 4/7 (57.1%) of anti-HBs responders achieving functional cure had baseline HBsAg levels between 1,154 and 3,086 IU/mL at enrollment in the prior BRII-179-835-001 study.After NA discontinuation,
More news about: Brii Biosciences Limited
May 27, 2026, 07:00 ET 騰盛博藥在EASL 2026發布ENSURE II期研究最新突破性數據，進一步支持BRII‑179對實現乙肝病毒持久免疫學控制的潛在作用
ENSURE研究（NCT05970289）是一項在亞太地區開展的多中心、開放標簽II期臨床研究。隊列1-3旨在評估研究性小干擾核糖核酸（siRNA）藥物elebsiran在慢性乙型肝炎病毒（HBV）感染參與者中，與PEG‑IFNα聯合治療時的療效貢獻，入組參與者的乙型肝炎表面抗原（HBsAg）基線水平為100–3,000 IU/mL。ENSURE研究的隊列4評估了一種用於慢性乙型肝炎的新型序貫聯合治療策略，利用騰盛博藥的治療性疫苗BRII‑179對參與者進行免疫激活和篩選，旨在提高其對治愈性治療的應答能力。該隊列納入了在既往2期研究BRII‑179‑835‑001（NCT04749368）中完成9劑BRII‑179和elebsiran治療的參與者，並接受為期48周的elebsiran與PEG‑IFNα聯合治療。根據既往研究中乙肝表面抗體（抗-HBs）峰值是否超過10
More news about: 騰盛博藥生物科技有限公司
May 27, 2026, 06:58 ET Tata Elxsi Launches AnaTel™, an AI-Native Software Development Platform for Healthcare and Med-Tech Powered by OpenAna
www.tataelxsi.comAbout OpenAna OpenAna is the creator of Ana, a Platform of Autonomous Engineers spanning software engineering, security, DevOps/SRE, and AI/ML, designed to transform how software is built and delivered at enterprise scale. Ana operates autonomously across the full engineering lifecycle, from
More news about: Tata Elxsi
May 27, 2026, 04:43 ET Foresee Pharmaceuticals Announces Completion of Casppian Phase 3 Study with Last Patient Last Visit and Confirms Topline Results: 94% of Patients Achieve LH Suppression with 6-Month Dosing Interval of Leuprolide Mesylate, also the acceptance of Casppian Study for Presentation at Endocrine Society, ENDO 2026 Medical Conference, as a Potential New Six-Month Treatment Option for Central Precocious Puberty
previously announced, the study's primary endpoint was defined as the percentage of patients with serum luteinizing hormone (LH) concentrations < 4 mIU/mL at 60 minutes following an abbreviated GnRHa stimulation test at Week 24. The results were statistically significant (P-value = 0.0005), with 94% of
More news about: Foresee Pharmaceuticals Co., Ltd.